Emergent BioSolutions (NSYE:EBS) announced today that it appointed Joseph C. Papa as its new president and CEO. Papa’s appointment to the corner office of the Gaithersburg, Maryland-based company went into effect today. He succeeds Haywood Miller, who stepped down from his role as interim CEO today as well. Emergent BioSolutions is known for its Narcan […]
Personnel
Enable Injections promotes COO from within
Wearable drug delivery technology maker Enable Injections announced today that it named David Kroekel as its new COO. Cincinnati-based Enable develops the enFuse platform, whichallows hands-free, hidden needle drug delivery of up to 25 mL. Its simple design enables flexibility for at-home self-administration or in-clinic use. The FDA cleared the system for the delivery of […]
Former Tandem CCO joins Ascensia as president of CGM
Ascensia Diabetes Care parent company PHC Holdings and Senseonics announced today that Ascensia named Brian Hansen its president of CGM. Hansen’s appointment to the newly created role at the global distributor of Senseonics’ Eversense CGM went into effect today, Feb. 6. Responsibilities for Hansen include the global commercialization and growth of the Eversense system. The fully […]
Insulet has new directors as former CEO is set to retire from board
Insulet (Nasdaq:PODD) announced today that it named a duo of new board directors with high-profile figures set to retire. Acton, Massachusetts-based Insulet appointed Flavia Pease and Timothy Stonesifer to its board. Former CEO Shacey Petrovic, along with Corinne Nevinny, intend to retire from the board in May. Petrovic spent more than seven years as CEO […]
Enable Injections adds finance veteran to its board
Enable Injections announced today that it appointed Vickie Capps to its board of directors as the head of the audit committee. Capps joins the wearable drug delivery system maker with plenty of experience in finance and executive leadership. She also brings extensive board experience, including currently serving on the board of orthopedic company NuVasive. Other […]
Insulet CFO departs for same post at 3M’s Health Care spinoff
Insulet (Nasdaq:PODD) announced today that Wayde McMillan decided to leave his role as EVP, CFO and treasurer. McMillan’s departure goes into effect on Oct. 20, 2023. He intends to join 3M as CFO of its Health Care business, which the company expects to spin off late this year or early next year. President and CEO […]
Ypsomed has a new CFO, board member
Ypsomed announced today that it selected Samuel Künzli to take over the company’s chief financial officer (CFO) position. Niklaus Ramseier elected to hand over the reins to the CFO position after more than 20 years in the post. The transition begins on March 31, 2024, with Ramseier remaining available to the drug delivery device maker […]
GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia
i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president and CEO. Graves previously served as executive chair of the i2o […]
Glucotrack tabs former Medtronic veteran for a board director spot
Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee. Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately. “We […]
Implantable CGM maker Glucotrack names new VP of marketing
Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing. Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device. […]
